11/21/2006 10:22:05 AM
REHOVOT, Israel--(BUSINESS WIRE)--Proteologics Ltd., a leader in ubiquitin research, announces the achievement of a major milestone in its collaboration with Teva. The alliance fortifies companies’ efforts in research, development and commercialization of novel anti-cancer therapeutics. Proteologics and Teva partner in two independent, yet complementary projects, focusing on specific components of the ubiquitin system. Successful identification and validation of a novel target triggered entrance into the second phase of the collaboration moving ahead into drug discovery. This progress follows the accomplishments of another joint Proteologics and Teva project, whereby small molecules are expected to enter animal tests later next year.
comments powered by